Top broker says buy ResMed and this ASX 200 share

Ord Minnett was impressed with their quarterly updates from last month.

| More on:
Happy shareholders clap and smile as they listen to a company earnings report.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A number of companies have released their quarterly updates in recent weeks.

Analysts at Ord Minnett have been running the rule over these updates and have picked out two ASX 200 shares that impressed enough to be rated as buys.

Here's what the broker is saying about them:

ResMed Inc. (ASX: RMD)

The first ASX 200 share that impressed is ResMed. It is a developer, manufacturer, distributor, and marketer of medical device and cloud-based software applications targeting the management of sleep apnoea.

Ord Minnett described ResMed's result as "strong" and has bumped its earnings estimates higher to reflect this and its positive outlook. It said:

The company delivered a strong September quarter result, with 11% revenue growth translating to 35% earnings per share growth. Revenues were 3% ahead of consensus due to higher rates of flow generator growth. ‍ The gross margin of 59.2% aligned with expectations, while operating expenses were slightly ahead of forecasts. ‍ Net operating cash flow increased by 14% compared to the previous corresponding period, despite higher inventory due to rebalancing sea versus air freight. Net debt fell, while the value of share buyback program was boosted.

ResMed upped it FY25 EPS guidance thanks to jump higher flow generator revenues. Revenue growth for the current quarter is forecast at 10%. We forecast the company will be able to generate annualised EPS growth of 13% for the next few years, which justifies its current trading multiples. We ticked our price target up from $39.25 to $40.05 following the quarterly.

Whitehaven Coal Ltd (ASX: WHC)

As well as ResMed shares, Ord Minnett is tipping Whitehaven Coal as an ASX 200 share to buy following the recent flurry of quarterly updates.

It develops and operates metallurgical and thermal coal mines in New South Wales and Queensland. ‍

Much like ResMed, the broker highlights that Whitehaven Coal delivered a solid quarterly update last month. It said:

The company had a solid September quarter of production and sales, with all mines delivering as planned or better. Group performance in Q1FY25 included managed run-of-mine production of 9.7Mt, and total equity sales of 6.4Mt. Net debt was $1.2 billion. ‍ Queensland operations achieved strong production and productivity improvements at Blackwater and Daunia, with run-of-mine (ROM)production up 11% and sales up 13%. Average coal price increased to $259/t. ‍

New South Wales saw improved Narrabri production and focused on overburden removal. Run-of-mine production was down 12%, with equity sales down 16%. Average coal price was $211/t. ‍ Run-of-mine coal production is expected to increase in the second half of FY25. Global metallurgical coal production shortfalls and increased Indian demand are expected to drive prices higher, which will benefit Whitehaven. ‍

In light of this, it has put a buy rating and $9.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Human head and artificial intelligence head side by side.
AI Stocks

The future of AI: Best ASX shares to buy now

Brokers are backing these 3 ASX shares for future growth amid the artificial intelligence revolution.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Broker Notes

These ASX shares could rise 19% and 35%

Analysts expect these shares to deliver big returns over the next 12 months.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Broker Notes

2 exciting ASX shares this fund manager thinks are buys

These stocks could be exciting opportunities to buy.

Read more »

Three happy construction workers on an infrastructure site have a chat.
Resources Shares

3 ASX lithium stocks primed for an electric performance: Macquarie

Time to charge up?

Read more »

Three happy multi-ethnic business colleagues discuss investment or finance possibilities in an office.
Broker Notes

ASX financial shares are up 33% this year. Brokers reveal which stocks to buy for 2025

After such a stellar run, are there any good buys left among ASX financial shares?

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Broker Notes

3 reasons to buy this ASX 200 stock now

Bell Potter thinks investors should be snapping up this stock right now.

Read more »